Tecentriq 1200mg 1s Injection

Vial per box: 1, Manufacturer: Roche

Description

Composition Atezolizumab
Substitutes Atezolizumab 1200mg 1s
Shipping class Cold chain shipment

Medicine Overview of Tecentriq 1200mg 1s Injection

uses

Uses of Tecentriq 1200mg 1s Injection

TECENTRIQ is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy.

uses

Tecentriq 1200mg 1s Injection side effects

Common

Immune-Mediated Pneumonitis, Immune-Mediated Hepatitis, Immune-Mediated Colitis, Immune-Mediated Endocrinopathies, Other Immune-Mediated Adverse Reactions, Infections, Infusion-Related Reactions
uses

How to use Tecentriq 1200mg 1s Injection

The recommended dosage of TECENTRIQ is 1200 mg as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.

How Tecentriq 1200mg 1s Injection works

Monoclonal antibody to programmed cell death ligand-1 protein (PDL1); binding PDL1 blocks the interaction between PDL-1 and its ligands. PDL1 is expressed on the surface of activated T cells under normal conditions; binding PDL1 inhibits immune activation and reduces T-cell cytotoxic activity when bound. This negative feedback loop is essential for maintaining normal immune responses and limits T-cell activity to protect normal cells during chronic inflammation. Tumor cells may circumvent T-cell–mediated cytotoxicity by expressing PDL1 on the tumor itself or on tumor-infiltrating immune cells, resulting in the inhibition of immune-mediated killing of tumor cells.

In Depth Information on Tecentriq 1200mg 1s Injection

Expert advice for Tecentriq 1200mg 1s Injection

  • Immune-related myasthenic syndrome/myasthenia gravis, Guillain Barré, or meningoencephalitis reported; permanently discontinue for any grade.
  • Monitor for clinical signs and symptoms of meningitis or encephalitis; permanently discontinue treatment for any grade of meningitis or encephalitis; treat with IV steroids (1-2 mg/kg/day methylprednisolone or equivalent) and convert to oral steroids (prednisone 60 mg/day or equivalent) once patient improves; when symptoms improve to Grade ≤1, taper steroids over ≥1 month.
  • Monitor for symptoms of motor and sensory neuropathy; permanently discontinue treatment for any grade of myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome; consider initiation of systemic corticosteroids at a dose of 1-2 mg/kg/day prednisone.
  • Symptomatic pancreatitis without an alternative etiology occurred in 0.1% of patients across clinical trials; monitor for signs and symptoms of acute pancreatitis.
  • Monitor for signs and symptoms of myocarditis.
  • Thyroid disorders may occur; monitor thyroid function prior to and periodically during treatment; initiate hormone replacement therapy or medical management of hyperthyroidism as clinically indicated; continue therapy for hypothyroidism and interrupt for hyperthyroidism based on severity.
  • Adrenal insufficiency may occur; monitor patients for clinical signs and symptoms of adrenal insufficiency; for Grade 2 or higher adrenal insufficiency, initiate prednisone 1-2 mg/kg/day or equivalents, followed by a taper and hormone replacement as clinically indicated; interrupt treatment based on severity.
  • Type 1 diabetes mellitus reported; monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated; interrupt treatment based on severity.
  • Hypophysitis/hypopituitarism may occur; for Grade 2 or higher hypophysitis, initiate prednisone 1-2 mg/kg/day or equivalents, followed by a taper and hormone replacement therapy as clinically indicated

Tecentriq 1200mg 1s Injection related warnings

Special precautions for Tecentriq 1200mg 1s Injection

alcohol
Alcohol
There is no significant data. Please consult your doctor.
pregnancy
Pregnancy
caution
Based on its mechanism of action, TECENTRIQ can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ in pregnant women.
lactation
Lactation
There is no information regarding the presence of atezolizumab in human milk, the effects on the breastfed infant, or the effects on milk production.
driving
Driving
There is no significant data. Please consult your doctor.
kidney
Kidney
Monitor the renal values.
liver
Liver
May cause liver test abnormalities and immune-mediated hepatitis; fatal cases reported; monitor for signs and symptoms of hepatitis, during and after discontinuation of therapy, including clinical chemistry monitoring; administer corticosteroids, prednisone 1–2 mg/kg/day or equivalents, followed by a taper for Grade 2 or higher elevations of ALT, AST and/or total bilirubin.

What if you miss a dose of Tecentriq 1200mg 1s Injection?

For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor or pharmacist right away to establish a new dosing schedule.